Barcelona 2015 Programme Registration Glaucoma Day 2015 Exhibition Virtual Exhibition Satellite Meetings Hotel Booking Star Alliance
ISTANBUL escrs









Take a look inside the London 2014 Congress

video-icon

Then register to join us
in Barcelona!





Trifocal IOL implantation to achieve better patient satisfaction: 3 year clinical results and quality of vision

Search Abstracts by author or title
(results will display both Free Papers & Poster)

Session Details

Session Title: Pseudophakic IOLs: Trifocal

Session Date/Time: Tuesday 08/09/2015 | 16:30-18:00

Paper Time: 17:14

Venue: Room 10

First Author: : M.Piovella ITALY

Co Author(s): :                        

Abstract Details

Purpose:

To evaluate visual and optical performances of cataract eyes after phacoemulsification and trifocal Intraocular Lens (IOL) (AT LISA tri 839MP, Carl Zeiss Meditec) implantation.

Setting:

Centro Microchirurgia Ambulatoriale, CMA, Monza, Italy

Methods:

76 eyes of 46 patients mean age: 64.22 ± 10.22 years underwent uncomplicated phacoemulsification and trifocal IOL (AT LISA tri 839 MP, Carl Zeiss Meditec) implantation. Preloaded IOL was implanted using a BLUEMIXS 180 injector. Postoperatively, the following visual and refractive parameters were measured: distance (5m) near (30cm) and intermediate (70 cm) visual acuity, corneal topography and aberrometry, contrast sensitivity and defocus curve. Regular follow-up examinations were performed up to 2 years after surgery.

Results:

Preoperative distance Uncorrected Visual Acuity (UCVA) was 0.30 ± 0.29. At 2 years, distance UCVA was 0.92 ± 0.08, monocular near vision was 20/22 and binocular near vision 20/22.5. Monocular intermediate vision was 20/30.83, binocular intermediate vision 20/22.

Conclusions:

AT LISA tri 839 MP provided good distance and near as well as intermediate visual acuity. This lens also improved quality of vision through remarkable diffraction efficiency while maintaining contrast sensitivity.

Financial Interest:

One of the authors receives consulting fees, retainer, or contract payments from a company producing, developing or supplying the product or procedure presented, One of the authors travel has been funded, fully or partially, by a company producing, developing or supplying the product or procedure presented, One of the authors receives consulting fees, retainer, or contract payments from a competing company

Back to previous